Chronic myeloid leukemia (CML) is a myeloproliferative disorder that is effectively treated with tyrosine kinase inhibitors (TKIs), targeting the BCR::ABL1 fusion protein. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.